Wells Fargo’s SYNAGEVA BIOPHARMA CORP COM STK (DE) GEVA Stock Holding History

Wells Fargo’s Portfolio GEVA Stock Details GEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q2	–	Sell	-797,807	Closed	-$77.8M	–	6725
2015 Q1	$77.8M	Buy	797,807 +363,265	+84%	+$38.5M	0.03%	596
2014 Q4	$40.3M	Sell	434,542 -143,718	-25%	-$11.3M	0.02%	880
2014 Q3	$39.8M	Buy	578,260 +565,457	+4,417%	+$40.5M	0.02%	854
2014 Q2	$1.34M	Sell	12,803 -100,780	-89%	-$8.57M	﹤0.01%	3297
2014 Q1	$9.42M	Buy	113,583 +95,362	+523%	+$8.82M	﹤0.01%	1835
2013 Q4	$1.18M	Sell	18,221 -25,683	-58%	-$1.52M	﹤0.01%	3308
2013 Q3	$2.78M	Sell	43,904 -165,838	-79%	-$8.16M	﹤0.01%	2643
2013 Q2	$8.8M	Buy	+209,742	New	+$9.56M	﹤0.01%	1677

Wells Fargo's GEVA Position: Q2 2015 in Review

Wells Fargo sold out of SYNAGEVA BIOPHARMA CORP COM STK (DE) (GEVA) in Q2 2015, closing a stake of 797,807 shares — an estimated $77.8M sold.

Wells Fargo first reported a position in GEVA in Q2 2013 and held it in 8 quarters. The position peaked at $77.8M in Q1 2015. 0 funds tracked by Wall St. Rank hold GEVA as of Q2 2015.

Wells Fargo reported no remaining SYNAGEVA BIOPHARMA CORP COM STK (DE) position as of Q2 2015 after selling out during the quarter.
Wells Fargo sold 797,807 SYNAGEVA BIOPHARMA CORP COM STK (DE) shares in Q2 2015, an estimated $77.8M.
Wells Fargo first reported a position in SYNAGEVA BIOPHARMA CORP COM STK (DE) in Q2 2013 and held it in 8 quarters.
Wells Fargo's SYNAGEVA BIOPHARMA CORP COM STK (DE) position peaked at $77.8M in Q1 2015.
0 funds tracked by Wall St. Rank held SYNAGEVA BIOPHARMA CORP COM STK (DE) as of Q2 2015.

Based on Wells Fargo's 13F filing for Q2 2015, filed 14 Aug 2015.